BioSpace News Archive

Exelixis, Inc. announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will participate in fireside chats at the following virtual investor conferences in May:.

Adaptimmune Therapeutics plc, a leader in cell therapy to treat cancer, will report initial preclinical data from its HLA Independent TCR targeting mesothelin, being co-developed with Astellas, during a poster presentation at the American Society for Cell and Gene Therapy meeting.

Pacific Biosciences of California, Inc. (Nasdaq: PACB), a leading provider of high-quality, long-read sequencing platforms, announced today that Dr. Hannah Valantine has been nominated for election to the Company’s Board of Directors as a Class II director at the Company’s 2021 Annual Meeting of Stockholders.

Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced that it will issue its financial results press release for the fiscal 2021 third quarter ended March 31, 2021

Aligos Therapeutics, Inc., a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, announced that the company has appointed James Scopa, J.D., MBA, to the Company’s board of directors.

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, announced that the Company has submitted its Marketing Authorization Application to the European Medicines Agency for omburtamab for the treatment of pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma.

NUPROBE GLOBAL, a molecular diagnostics company based in Shanghai, China and Houston, Texas, has reached a strategic collaboration agreement with AcornMed Biotechnology Co., Ltd.

Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, announced the Company took part in an informal meeting with the U.S. Food and Drug Administration on April 23, 2021, in connection with the FDA’s ongoing review of the teplizumab Biologic License Application for the delay or prevention of clinical type 1 diabetes.

Outset Medical, Inc., a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, announced that members of management will participate in a fireside chat at the BofA Securities 2021 Virtual Health Care Conference on Tuesday, May 11, 2021 at 11:45am PT / 2:45pm ET.

LeMaitre Vascular, Inc. announced that it is participating in two investor conferences in May.